<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03497338</url>
  </required_header>
  <id_info>
    <org_study_id>new anticoagulation of ECMO</org_study_id>
    <nct_id>NCT03497338</nct_id>
  </id_info>
  <brief_title>New Anticoagulation Strategies of VV-ECMO</brief_title>
  <official_title>the Efficacy and Safety of New Anticoagulation Strategies of Maintain Normal Clot Rate to Prevent Hemorrhage While VV-ECMO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiao Tang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effective and normative anticoagulation is one of the most important components of
      Extracorporeal membrane oxygenation (ECMO) management. Excessive anticoagulation may lead to
      hemorrhage, which is the most common and serious complication. Currently, the most common
      factors for monitoring anticoagulation of ECMO are the activated clotting time (ACT) and
      activated partial thromboplastin time (APTT). However, there is a lack of a unified
      understanding of the related monitoring measures, monitoring targets, and bleeding risk
      assessments, which have been chosen mainly because of experiences reported by various ECMO
      centers or the results of retrospective studies.Therefore, anticoagulation strategies need to
      be improved. Our research have found ECMO anticoagulation management should be transformed
      from monitoring only the APTT/activated clotting time (ACT) to considering the entire
      coagulation process. To maintain thrombosis ability and PLT function within normal ranges may
      help reduce hemorrhage rates and improve prognoses. This randomized controlled study aim to
      develop the safety and efficacy new anticoagulation strategies of VV-ECMO.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with hemorrhage events</measure>
    <time_frame>4 weeks</time_frame>
    <description>1) fatal bleeding; 2) symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome; and/or 3. bleeding causing a drop in hemoglobin level by 20 g/L or more or requiring transfusion of two units of whole blood or red cells.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>new anticoagulation strategy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>tradition strategy group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>thrombelastogram，D-Dimer，APTT</intervention_name>
    <description>monitoring thrombelastogram to control the clot rate in the normal range to adjust the heparin dose</description>
    <arm_group_label>new anticoagulation strategy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age more than 18 years old, VV-ECMO is estimated more than 3 days

        Exclusion Criteria:

          -  hemorrhage before VV-ECMO established, VV-ECMO more than 48 hours before admitted,
             VV-ECMO is estimated less than 3 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bing Sun, MD</last_name>
    <phone>86013911151075</phone>
    <email>ricusunbing@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao Tang, MD</last_name>
    <phone>86013811089795</phone>
    <email>tangxiao0928@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of respiratory and critical care medicine,Beijing Chao-yang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bing Sun, MD</last_name>
      <phone>86013911151075</phone>
      <email>ricusunbing@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiao Tang, MD</last_name>
      <phone>86013811089795</phone>
      <email>tangxiao0928@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bing Sun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2018</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Xiao Tang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

